New drug aims to stop transplant rejection in High-Risk patients
NCT ID NCT07244419
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether a drug called emapalumab can prevent the body from rejecting a stem cell transplant. The study will include 20 patients who are at high risk for rejection. Researchers will also study how the drug works in the body to improve future treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can gut bacteria help rebuild immunity after stem cell transplants?
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Could virtual reality help patients recover faster from cell therapy?
- Which graft works best for Second-Time ACL surgery?
- Tailored drug dosing may cut infections after stem cell transplants
- Herbal granules aim to lift mood in transplant survivors